JP2015524391A5 - - Google Patents

Download PDF

Info

Publication number
JP2015524391A5
JP2015524391A5 JP2015520598A JP2015520598A JP2015524391A5 JP 2015524391 A5 JP2015524391 A5 JP 2015524391A5 JP 2015520598 A JP2015520598 A JP 2015520598A JP 2015520598 A JP2015520598 A JP 2015520598A JP 2015524391 A5 JP2015524391 A5 JP 2015524391A5
Authority
JP
Japan
Prior art keywords
composition
diffraction peak
crystal form
anhydride
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2015520598A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015524391A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/048723 external-priority patent/WO2014005098A2/en
Publication of JP2015524391A publication Critical patent/JP2015524391A/ja
Publication of JP2015524391A5 publication Critical patent/JP2015524391A5/ja
Withdrawn legal-status Critical Current

Links

JP2015520598A 2012-06-29 2013-06-28 ニューモウイルス感染症および感染疾患を治療あるいは予防するための組成物および方法 Withdrawn JP2015524391A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261666258P 2012-06-29 2012-06-29
US61/666,258 2012-06-29
PCT/US2013/048723 WO2014005098A2 (en) 2012-06-29 2013-06-28 Compositions and methods for treating or preventing pneumovirus infection and associated diseases

Publications (2)

Publication Number Publication Date
JP2015524391A JP2015524391A (ja) 2015-08-24
JP2015524391A5 true JP2015524391A5 (enExample) 2016-08-18

Family

ID=49778754

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015520598A Withdrawn JP2015524391A (ja) 2012-06-29 2013-06-28 ニューモウイルス感染症および感染疾患を治療あるいは予防するための組成物および方法

Country Status (17)

Country Link
US (2) US9040569B2 (enExample)
EP (1) EP2867216A4 (enExample)
JP (1) JP2015524391A (enExample)
KR (1) KR20150037946A (enExample)
CN (1) CN104507918A (enExample)
AU (1) AU2013282286A1 (enExample)
BR (1) BR112014032290A2 (enExample)
CA (1) CA2877941A1 (enExample)
EA (1) EA201590124A1 (enExample)
HK (2) HK1203956A1 (enExample)
IL (1) IL236476A0 (enExample)
IN (1) IN2014DN10680A (enExample)
MX (1) MX2014015340A (enExample)
NZ (1) NZ628880A (enExample)
TW (1) TWI516283B (enExample)
WO (1) WO2014005098A2 (enExample)
ZA (1) ZA201409073B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2867216A4 (en) 2012-06-29 2015-12-09 Microdose Therapeutx Inc COMPOSITIONS AND METHODS OF TREATING PNEUMOVIRAL INFECTIONS AND ASSOCIATED DISEASES
EP3233807B1 (de) * 2014-12-18 2019-09-04 MetrioPharm AG Kristalline form von 5-amino-2,3-dihydrophthalazin-1,4-dion natriumsalz, diese enthaltende pharmazeutische zubereitungen und verfahren zu ihrer herstellung
JP2018535277A (ja) * 2015-11-30 2018-11-29 ノヴァス・セラピューティクス・インコーポレーテッド 耳科学的予防および処置のための組成物および方法
WO2018071445A1 (en) 2016-10-11 2018-04-19 Microdose Therapeutx, Inc. Inhaler and methods of use thereof
MX2021001820A (es) * 2018-09-14 2021-04-28 Pharmosa Biopharm Inc Composicion farmaceutica para la liberacion controlada de farmacos acidos debiles y usos de los mismos.
CN109827875A (zh) * 2019-04-10 2019-05-31 上海市食品药品检验所 一种用于测定吸入制剂溶出度的装置和方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6495580B1 (en) * 1998-01-29 2002-12-17 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO1999038508A1 (en) 1998-01-29 1999-08-05 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
WO2002059132A1 (en) 2001-01-26 2002-08-01 Viropharma Incorporated Intermediate compounds useful for making antiviral compounds
EP1545513A2 (en) 2002-08-09 2005-06-29 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP1539691A2 (en) 2002-08-09 2005-06-15 Viropharma Incorporated Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases
EP2867216A4 (en) 2012-06-29 2015-12-09 Microdose Therapeutx Inc COMPOSITIONS AND METHODS OF TREATING PNEUMOVIRAL INFECTIONS AND ASSOCIATED DISEASES

Similar Documents

Publication Publication Date Title
JP2015524391A5 (enExample)
EA201591390A1 (ru) Пиразол[1,5-a]пиримидины для противовирусного лечения
NZ701647A (en) Compounds and methods for antiviral treatment
CA2818938A1 (en) Compounds for treating respiratory syncytial virus infections
AU2012358805A8 (en) Pyrazolo[1,5-a]pyrimidines as antiviral agents
AP3103A (en) Derivatives of purine or deazapurine useful for the treatment of (inter alia)viral infections
ATE541845T1 (de) 2,3-substituierte azaindolderivate zur behandlung von virusinfektionen
JP2015512931A5 (enExample)
WO2012027712A3 (en) Potent and selective inhibitors of hepatitis c virus
IL227990B (en) Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione for preparation of medicaments for treatment of immune-related and inflammatory diseases
EA201100613A1 (ru) Конденсированные, спироциклические гетероароматические соединения для лечения бактериальных инфекций
ES2855159T8 (es) Tratamiento de las infecciones pulmonares mediante administración de tobramicina por aerolización
HUE036220T2 (hu) Kinazolin származékok vírusfertõzések és további betegségek kezelésére
WO2011158042A3 (en) Ureido- pyrazole derivatives for use in the treatment of rhinovirus infections
UA111163C2 (uk) Способи й сполуки для лікування вірусних інфекцій paramyxoviridae
EP2760479A4 (en) METHOD FOR THE THERAPEUTIC MONITORING OF NITROGEN ABSORPTION ACTIVE SUBSTANCES
WO2013055258A3 (ru) Применение глутарилгистамина для лечения заболеваний дыхательных путей
CL2013002031A1 (es) Dimaleato de 9-[4-(3-cloro-2-fluoro-fenilamino)-7-metoxi-quinazolin-6-il oxi]-1-metil-1,4-diaza-espiro[5.5]undecan-5-ona; forma cristalina; compuestos intermediarios; procedimiento de preparacion; composicion y combinacion farmaceutica; y su uso para tratar enfermedades infecciosas o alergicas de las vias respiratorias.
TW201613931A (en) Form crystal of bisulfate of janus kinase (JAK) inhibitor and preparation method thereof
IN2012DN06678A (enExample)
WO2010135170A3 (en) Nitrile derivatives and their pharmaceutical use and compositions
WO2014005098A3 (en) Compositions and methods for treating or preventing pneumovirus infection and associated diseases
MX2013002956A (es) Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central.
PL2291374T3 (pl) Sposób wytwarzania solifenacyny i/lub jej farmaceutycznie dopuszczalnych soli o wysokiej czystości farmaceutycznej
WO2012122450A3 (en) Peptide deformylase inhibitors